一分钟看懂
这是一项关于乳腺癌的III 期研究，登记的药物或干预包括Phesgo；Giredestrant；Docetaxel；Paclitaxel；LHRH Agonist；Optional Endocrine Therapy of Investigator's Choice，当前状态为研究进行中，已停止招募。登记地点显示中国保定、北京、蚌埠、长春等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Phesgo；Giredestrant；Docetaxel；Paclitaxel；LHRH Agonist；Optional Endocrine Therapy of Investigator's Choice · III 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Affiliated Hospital of Hebei University · 保定
- Peking University People's Hospital · 北京
- the First Affiliated Hospital of Bengbu Medical College · 蚌埠
- The First Hospital of Jilin University · 长春
- Hunan Cancer Hospital · 长沙
- Sichuan Cancer Hospital · 成都
- West China Hospital - Sichuan University · 成都
- No. 900 Hospital (Fuzhou General Hospital) · 福州
- Fujian Cancer Hospital · 福州
- Zhejiang Provincial People?s Hospital · 杭州
- Zhejiang Cancer Hospital · 杭州
- Shandong Cancer Hospital · 济南
- The First Affiliated Hospital Of Jinzhou Medical University · Jinzhou
- Yunnan Cancer Hospital · 昆明
- Jiangxi Cancer Hospital · 南昌
- Jiangsu Cancer Hospital · 南京
- Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University) · 南京
- Guangxi Cancer Hospital of Guangxi Medical University · 南宁
- The First Affiliated Hospital of China Medical University · 沈阳
- Tianjin Cancer Hospital · 天津
- The Tumor Hospital of Xinjiang Medical University · 乌鲁木齐
- Union Hospital Tongji Medical College Huazhong University of Science and Technology · 武汉
- The First Affiliated Hospital of Xian Jiao Tong University · 西安
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Histologically or cytologically confirmed and documented human epidermal growth factor receptor 2 (HER2)-positive/estrogen receptor (ER)-positive adenocarcinoma of the breast with metastatic or locally-advanced disease not amenable to curative resection
- * At least one measurable lesion and/or non-measurable disease evaluable according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
- * Disease-free interval from completion of adjuvant or neoadjuvant systemic non-hormonal treatment to recurrence of ≥6 months
- * Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
- * Left ventricular ejection fraction (LVEF) of at least (≥)50% measured by echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA)
- * Adequate hematologic and end-organ function
- * For women of childbearing potential: Participants who agree to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agree to refrain from donating eggs, during the treatment period and for 7 months after the final dose of Phesgo
- * For men: participants who agree to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agree to refrain from donating sperm, during the treatment period and for 7 months after the final dose of Phesgo to avoid exposing the embryo
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05296798；登记信息更新于 2026-10-02；本站同步于 2026-10-08。